BOREHAMWOOD, ENGLAND, September 13, 2013 /**24-7PressRelease**/ -- Pharmarama knows just how debilitating knee pain can be, particularly for those who are suffering from osteoarthritis. For this reason, they applaud a new article that describes a drug that may significantly reduce osteoarthritis-related knee pain in patients. Colorado-based Ampion Pharmaceuticals reveals that osteoarthritis patients who were injected with the experimental anti-inflammatory drug Ampion were found to have significantly reduced knee pain levels in a late-stage clinical trial. The company hopes that this medication could eventually be used to soothe a wide range of inflammatory diseases.

The Phase III study of 329 patients with osteoarthritis had some participants get injected with one or two doses of Ampion, while the others only received a saline injection. Those who got a single injection of the drug saw an average of a 40 percent reduction in knee pain, along with a substantial boost in knee function and quality of life throughout the study, which lasted for 12 weeks. The professionals at Ampion explained that there were no major differences in the effectiveness between the two Ampion doses. The optimal dose will be selected with help from the Food and Drug Administration in time for a second Phase III trial.

Brian McGrath, the principal investigator and an orthopedic surgeon at University Orthopedics Services in Amherst, New York comments, "This is fantastic. These results highlight the strong possibility that it may soon be possible to offer patients an effective therapy."

Osteoarthritis is a highly common form of arthritis that impacts over 27 million people in the United States today. It is a progressive joint disorder that is caused by inflammation in the soft tissue. It worsens over time and eventually leads to the thinning of cartilage.

Nathan Wei, a rheumatologist at the Arthritis Treatment Center in Frederick, Maryland, says, "I was pleasantly surprised at the positive response rate in patients with otherwise intractable osteoarthritis of the knee. I am also hoping to study Ampion injections into the base of the thumb and base of the toe, for which there is no current therapy."

Ampion is currently being developed as a non-steroidal injection that treats diseases that relate to inflammation. It comes from a molecule that is thought to cut down on inflammation as it suppresses pro-inflammatory cytokine production in T-cells. The makers of Ampion believe that it has the ability to be used in a wide variety of acute and chronic inflammatory conditions. This includes osteoarthritis, rheumatoid arthritis, and autoimmune diseases.

The professionals at Pharmarama reflect on the development of this potential new solution to osteoarthritis pain by saying, "The results that have been released from Phase III of the clinical trial on this new treatment show great promise for a product that has the potential to benefit the lives of millions globally. Osteoarthritis is a common problem and the results of this new therapy will be exciting news for patients who have long suffered from this condition and where current readily available treatments haven't alleviated the symptoms." The professionals at Pharmarama go on to add, "Pharmarama International Limited specializes in the importation of unlicensed medicines and named patient programs, where the company looks to work in partnership with regulatory authorities, manufacturers and physicians to potentially make available a product that is currently unlicensed in a territory.

ABOUT:

Pharmarama is a well-respected wholesaler and importer of licensed and unlicensed medication. For over 13 years, they have provided industry leading service and forward thinking customer care to United Kingdom Pharmacists and Hospitals. Furthermore, their worldwide network of direct-from-manufacturer drug sourcing allows them to support third party clinical studies via validated comparator supply.